Table 1.
Patient characteristics
| (n = 78) | ||
|---|---|---|
| Age (years) |
70 (50–88) |
|
| PSA at PCa diagnosis (ng/mL) |
124.6 (4.7-19523.1) |
|
| PSA at DTX initiation (ng/mL) |
19.7 (0.6-1053.0) |
|
| Time from PCa diagnosis to DTX initiation (months) |
37 (4–189) |
|
| PSADT (months) |
2.4 (0.6-33.9) |
|
| ECOG performance status, n (%) |
|
|
| 0 |
|
40 (51) |
| 1 |
|
28 (36) |
| 2 |
|
10 (13) |
| Gleason score, n (%) |
|
|
| <6 |
|
5 (6) |
| 7 |
|
16 (21) |
| >8 |
|
50 (64) |
| Unknown |
|
7 (9) |
| Metastatic site, n (%) |
|
|
| Bone |
|
42 (54) |
| Lymph nodes |
|
19 (24) |
| Liver |
|
3 (4) |
| Lung |
|
1 (1) |
| None |
|
28 (36) |
| Bone scan progression, n (%) |
|
|
| Yes |
|
15 (19) |
| No |
|
63 (81) |
| Pain at baseline, n (%) |
|
|
| Yes |
|
24 (31) |
| No |
|
54 (69) |
| Haemoglobin (g/dL) |
11.8 (8.4-14.1) |
|
| ALP (IU/L) |
290 (59–8689) |
|
| Prior treatment, n (%) |
|
|
| Combined androgen blockade |
|
78 (100) |
| Prostatectomy |
|
3 (4) |
| Radiotherapy |
|
10 (13) |
| Estramustine |
|
69 (88) |
| No. of DTX cycles | 5 (2–46) | |
Abbreviations: PSA, prostate-specific antigen; PCa, prostate cancer; DTX, docetaxel; PSADT, prostate-specific antigen doubling time; ECOG, Eastern Cooperative Oncology Group; ALP, alkaline phosphatase. All continuous data are described in median (range).